FDA is allowing Boston Scientific to resume defibrillator sales. Sales were halted due to manufacturing process changes that had not been approved by the agency. Both the company and FDA say that the changes did not affect the safety of the defibrillators, which send electrical jolts to the heart to regulate heartbeat.